Wednesday, December 28, 2005

Letrozole Improves Breast Cancer Survival

Forbes, December 28, 2005
Postmenopausal breast cancer patients who take letrozole, one of a new class of drugs called aromatase inhibitors, reduce their risk of cancer recurrence compared with women taking tamoxifen, a breast cancer drug used widely for more than two decades, researchers report. Tamoxifen has greatly reduced the risk of recurrence and death in women who have estrogen-receptor-positive breast cancer, meaning cancer that is fueled by the hormone estrogen. The drug reduces the risk of recurrence by 47 percent and the risk of death by 26 percent for five years after surgery. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */